Background: Patients with COVID-19 are at a high risk for the development of venous thromboembolic disease [Link is HERE]. Alveolar capillary microthrombi appear to be 9x more prevalent in patients with COVID-19 compared to H1N1. As a result, enhanced-dose anticoagulation has been recommended and practiced by many caring for these patients.  However, the effectiveness and … Continue reading COVID-19 and Anticoagulation: Full Dose or Prophylactic Dose?